Literature DB >> 18410892

The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.

Heather J Symons1, Moshe Y Levy, Jie Wang, Xiaotao Zhou, Gang Zhou, Sarah E Cohen, Leo Luznik, Hyam I Levitsky, Ephraim J Fuchs.   

Abstract

The "allogeneic effect" refers to the induction of host B cell antibody synthesis or host T cell cytotoxicity, including tumoricidal activity, by an infusion of allogeneic lymphocytes. We show that treatment of mice with cyclophosphamide (Cy) followed by CD8(+) T cell-depleted allogeneic donor lymphocyte infusion (Cy + CD8(-) DLI) induces regression of established tumors with minimal toxicity in models of both hematologic and solid cancers, even though the donor cells are eventually rejected by the host immune system. The optimal antitumor effect of Cy + CD8(-) DLI required the presence of donor CD4(+) T cells, host CD8(+) T cells, and alloantigen expression by normal host but not tumor tissue. The results support a model in which a donor CD4(+) T cell-mediated graft-versus-host (GVH) reaction effectively awakens antitumor immunity among Cy-resistant host CD8(+) T cells. These events provide the cellular mechanism of the "allogeneic effect" in antitumor immunity. Cy + CD8(-) DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410892      PMCID: PMC2377414          DOI: 10.1016/j.bbmt.2008.02.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  62 in total

1.  CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Authors:  Paul A Antony; Ciriaco A Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas C Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

2.  Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

Authors:  C Schmaltz; O Alpdogan; K J Horndasch; S J Muriglan; B J Kappel; T Teshima; J L Ferrara; S J Burakoff; M R van den Brink
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

Review 3.  Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

Authors:  Claudia Wrzesinski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2005-04       Impact factor: 7.486

4.  Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.

Authors:  Bimalangshu R Dey; Steven McAfee; Christine Colby; Kathy Cieply; Martin Caron; Susan Saidman; Frederic Preffer; Juanita Shaffer; Nancy Tarbell; Robert Sackstein; David Sachs; Megan Sykes; Thomas R Spitzer
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

5.  Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.

Authors:  Ian E Brown; Christian Blank; Justin Kline; Aalok K Kacha; Thomas F Gajewski
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

6.  Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.

Authors:  D L Porter; J M Connors; V M Van Deerlin; K M Duffy; C McGarigle; S L Saidman; D G Leonard; J H Antin
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

7.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

Authors:  H L Hanson; D L Donermeyer; H Ikeda; J M White; V Shankaran; L J Old; H Shiku; R D Schreiber; P M Allen
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

8.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

9.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.

Authors:  Didier Blaise; Jacques Olivier Bay; Catherine Faucher; Mauricette Michallet; Jean-Michel Boiron; Bachra Choufi; Jean-Yves Cahn; Nicole Gratecos; Jean-Jacques Sotto; Sylvie François; Joel Fleury; Mohamad Mohty; Christian Chabannon; Karin Bilger; Gwenaelle Gravis; Frédéric Viret; Anne Chantal Braud; Valérie Jeanne Bardou; Dominique Maraninchi; Patrice Viens
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

10.  Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Authors:  Gang Zhou; Zhengbin Lu; John D McCadden; Hyam I Levitsky; Aimee L Marson
Journal:  J Exp Med       Date:  2004-12-13       Impact factor: 14.307

View more
  12 in total

1.  Adoptive immunotherapy for myeloid malignancies.

Authors:  J L Reagan
Journal:  Leuk Suppl       Date:  2014-12-17

Review 2.  Haploidentical transplantation for hematologic malignancies: where do we stand?

Authors:  Ephraim J Fuchs
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 3.  Clinical Studies in Hematologic Microtransplantation.

Authors:  Kevin A David; Dennis Cooper; Roger Strair
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

4.  Cooperation of CD4+ T cells and CD8+ T cells and release of IFN-γ are critical for antileukemia responses of recipient mice treated by microtransplantation.

Authors:  Li Wang; Fan Du; Hongxiang Wang; Conghua Xie
Journal:  Exp Ther Med       Date:  2017-11-22       Impact factor: 2.447

Review 5.  Transplantation tolerance: from theory to clinic.

Authors:  Ephraim J Fuchs
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

Review 6.  High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.

Authors:  Leo Luznik; Ephraim J Fuchs
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 7.  Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.

Authors:  Monzr M Al Malki; Richard Jones; Qing Ma; Dean Lee; Yair Reisner; Jeffrey S Miller; Peter Lang; Suradej Hongeng; Parameswaran Hari; Samuel Strober; Jianhua Yu; Richard Maziarz; Domenico Mavilio; Denis-Claude Roy; Chiara Bonini; Richard E Champlin; Ephraim J Fuchs; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-12       Impact factor: 5.742

Review 8.  The Principles of Engineering Immune Cells to Treat Cancer.

Authors:  Wendell A Lim; Carl H June
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

9.  Irradiation of donor mononuclear cells for treatment of chemorefractory metastatic solid cancers: a community-based immune transplant pilot study.

Authors:  John T Reynolds; John M Watkins; Tarek A Dufan; Shrikant S Kubsad
Journal:  Cancer Res Treat       Date:  2012-06-30       Impact factor: 4.679

10.  HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.

Authors:  Ephraim J Fuchs; Shannon R McCurdy; Scott R Solomon; Tao Wang; Megan R Herr; Dipenkumar Modi; Michael R Grunwald; Taiga Nishihori; Michelle Kuxhausen; Stephanie Fingerson; Caroline McKallor; Asad Bashey; Yvette L Kasamon; Yung-Tsi Bolon; Ayman Saad; Joseph McGuirk; Sophie Paczesny; Shahinaz M Gadalla; Steven G E Marsh; Bronwen E Shaw; Stephen R Spellman; Stephanie J Lee; Effie W Petersdorf
Journal:  Blood       Date:  2022-03-10       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.